


## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

### LISTING OF CLAIMS:

1. (currently amended): A method for treating obesity in a mammalian subject, which comprises administration of an effective amount of a prostaglandin compound to the subject as shown by the following formula (I):




wherein L, M and N are hydrogen atom, hydroxy, halogen atom, lower alkyl, hydroxy(lower)alkyl, lower alkanoyloxy or oxo, wherein at least one of L and M is a group other than hydrogen, and the five-membered ring may have at least one double bond;

A is -CH<sub>3</sub>, or -CH<sub>2</sub>OH, -COCH<sub>2</sub>OH, -COOH or a salt, ether, ester or amide thereof;

B is single bond, -CH<sub>2</sub>-CH<sub>2</sub>-, -CH=CH-, -C≡C-, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-, -CH=CH-CH<sub>2</sub>-, -CH<sub>2</sub>-CH=CH-, -C≡C-CH<sub>2</sub>- or -CH<sub>2</sub>-C≡C-;

Z is



wherein R<sub>4</sub> and R<sub>5</sub> are hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or hydroxy(lower)alkyl, wherein R<sub>4</sub> and R<sub>5</sub> are not hydroxy and lower alkoxy at the same time;

R<sub>1</sub> is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, alkyl, hydroxy, oxo, aryl selected from the group consisting of phenyl, tolyl and xylyl which is unsubstituted or substituted or heterocyclic group selected from the group consisting of furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, furazanyl, pyranyl, pyridyl, pyridazinyl, pyrimidyl, pyrazinyl, 2-pyrrolinyl, pyrrolidinyl, 2-imidazolyl, imidazolidinyl, 2-pyrazolyl, pyrazolidinyl, piperidino, piperazinyl, morpholino, indolyl, benzothienyl, quinolyl, isoquinolyl, purinyl, quinazolinyl, carbazolyl, acridinyl, phenanthridinyl, benzimidazolyl, benzimidazolinyl, benzothiazolyl and phenothiazinyl which is unsubstituted or substituted, and at least one carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur; and

R<sub>a</sub> is a saturated or unsaturated lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, oxo, hydroxy, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, cyclo(lower)alkyloxy, aryl, aryloxy, heterocyclic group and heterocyclic-oxy group; lower alkoxy; lower alkanoyloxy; cyclo(lower)alkyl; cyclo(lower)alkyloxy; aryl; aryloxy; heterocyclic group; or heterocyclic-oxy, provided that Z is C=O and/or R<sub>a</sub> is a saturated or unsaturated lower or medium aliphatic hydrocarbon residue which has a halogen substituent.

2. (canceled).

3. (currently amended): The method as described in Claim 1, wherein said prostaglandin compound is a 16-mono or dihalogen-prostaglandin compound.

4. (currently amended): The method as described in Claim 1, wherein said prostaglandin compound is a 13,14-dihydro-16-mono or dihalogen-prostaglandin compound.

5. (currently amended): The method as described in Claim 1, wherein said prostaglandin compound is a 13,14-dihydro-15-keto-16-mono or dihalogen-prostaglandin compound.

6. (currently amended): The method as described in Claim 1, wherein said prostaglandin compound is a 13,14-dihydro-16-mono or difluoro-prostaglandin compound.

7. (currently amended): The method as described in Claim 1, wherein said prostaglandin compound is a 13,14-dihydro-15-keto-16-mono or difluoro-prostaglandin compound.

8. (currently amended): The method as described in Claim 1, wherein said prostaglandin compound is a 13,14-dihydro-16-mono or dihalogen-prostaglandin E compound.

9. (currently amended): The method as described in Claim 1, wherein said prostaglandin compound is a 13,14-dihydro-15-keto-16-mono or dihalogen-prostaglandin E compound.

10. (currently amended): The method as described in Claim 1, wherein said prostaglandin compound is a 13,14-dihydro-16,16-difluoro-prostaglandin E<sub>1</sub> compound.

11. (currently amended): The method as described in Claim 1, wherein said prostaglandin compound is a 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E<sub>1</sub> compound or 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E<sub>1</sub> compound.

12. (original): The method as described in Claim 1, which comprises systemic administration 1-4 times per day or continuous administration at the amount of 0.01-100  $\mu\text{g/kg}$  per day.

13. (original): The method as described in Claim 12, wherein the administration is at the amount of 0.1-10  $\mu\text{g/kg}$  per day.

14. (canceled).

15. (canceled).

16. (new) The method as described in Claim 1, wherein Z is C=O.

17. (new) The method as described in Claim 1, wherein Ra is a saturated or unsaturated lower or medium aliphatic hydrocarbon residue which has a halogen substituent.